Exponent Reports Third Quarter of Fiscal Year 2025 Financial Results

Rhea-AI Summary

Exponent (Nasdaq: EXPO) reported third-quarter fiscal 2025 results for the period ended October 3, 2025. Q3 revenues rose 8% to $147.1M and revenues before reimbursements rose 10% to $137.1M. Net income was $28.0M, or $0.55 diluted EPS. EBITDA was $38.8M (28.3% of revenues before reimbursements). Year-to-date revenues rose 3% to $434.6M while net income decreased to $81.2M. The company paid $46.7M in dividends, repurchased $72.7M of stock, and ended the period with $207.4M cash. The Board approved a $100M increase to the buyback program and declared a $0.30 quarterly dividend.

Q4 and full-year 2025 guidance includes modest revenue growth and EBITDA margin ranges of 26.0%–27.0% (Q4) and 27.4%–27.65% (full year).

Positive

• Revenues before reimbursements +10% in Q3 2025
• Net income of $28.0M (Q3 2025) or $0.55 diluted EPS
• Board approved $100M increase to share repurchase authorization
• Declared quarterly dividend of $0.30; $46.7M paid YTD

Negative

• Return to a 13-week Q4 creates a timing headwind vs prior-year 14th week
• Full-year comparisons face a headwind from returning to a 52-week year vs fiscal 2024's 53rd week
• Year-to-date net income decreased to $81.2M through three quarters of 2025

Insights

Equity Analyst

Quarter showed modest revenue and EBITDA growth, mixed year‑to‑date results, and shareholder returns increased.

Exponent, Inc. reported third‑quarter revenues of $147.1 million (total) and $137.1 million (before reimbursements), up 8% and 10% year‑over‑year respectively; quarterly net income rose to $28.0 million ($0.55 per diluted share) and EBITDA increased to $38.8 million or 28.3% of revenues before reimbursements.

Through the first three quarters, revenues grew 3% to $434.6 million (total) and $407.4 million (before reimbursements), while net income declined to $81.2 million ($1.58 per diluted share) and EBITDA fell to $113.4 million or 27.8% of revenues before reimbursements; the release attributes part of the year‑over‑year tax variance to share‑based award impacts.

The company signaled steady near‑term performance by maintaining revenue guidance and raising margin guidance for the full year, provided ranges for Q4 EBITDA margin of 26.0% to 27.0% and full‑year EBITDA margin of 27.4% to 27.65%, announced a quarterly cash dividend of $0.30 payable on December 19, 2025, and increased the share repurchase authorization by $100 million.

Key dependencies and risks are explicit: comparisons face calendar‑week headwinds versus fiscal 2024 due to a return to a 52‑week year and a shorter Q4; tax treatment of share‑based awards materially affected year‑to‑date net income; and management cites sector‑specific demand shifts (e.g., dispute work vs consumer electronics). Watch the company’s Q4 revenue growth versus the extra‑week adjustment and whether EBITDA margins track the guided 26–27.65% band within the next quarter and full fiscal year.

MENLO PARK, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the third quarter of fiscal year 2025 ended October 3, 2025.

“Exponent delivered a strong third quarter, achieving double digit net revenue growth that reflects the strength of our diversified portfolio and our ability to deliver value across industries,” stated Dr. Catherine Corrigan, President and Chief Executive Officer. “Increasing demand for dispute-related work drove robust growth in reactive engagements across the energy, transportation, life sciences and construction sectors. Proactive engagements were led by risk management and asset integrity projects in the utilities sector and regulatory consulting in the chemical sector. While these were offset by lower activity in consumer electronics, we are encouraged by improving demand trends in this space as we enter the fourth quarter.

“As artificial intelligence is increasingly integrated into safety-critical systems, Exponent is helping clients navigate risk and innovate responsibly. From automotive and utilities to life sciences and consumer products, our teams are at the forefront of addressing the increasingly complex technical and human-machine challenges that accompany rapid technological change. As innovation accelerates, so does our differentiation, driven by a one-of-a-kind, integrated ecosystem of experts that is uniquely positioned to tackle complex challenges while capturing new opportunities for growth,” Dr. Corrigan continued.

Third Quarter Financial Results

Total revenues and revenues before reimbursements for the third quarter of 2025 increased 8% to $147.1 million and 10% to $137.1 million, respectively, as compared to $136.3 million and $125.1 million in the third quarter of 2024.

Net income increased to $28.0 million, or $0.55 per diluted share, in the third quarter of 2025, as compared to $26.0 million, or $0.50 per diluted share, in the same period of 2024. The tax benefit for the classification of tax adjustments associated with share-based awards was $0.1 million in the third quarter of 2025 as compared to $0.5 million in the third quarter of 2024. Inclusive of the tax benefit, Exponent’s consolidated tax rate was 27.4% in the third quarter, as compared to 27.5% for the same period in 2024.

EBITDA¹ increased to $38.8 million, or 28.3% of revenues before reimbursements, in the third quarter of 2025, as compared to $35.8 million, or 28.6% of revenues before reimbursements in the third quarter of 2024.

Year to Date Financial Results

Total revenues and revenues before reimbursements for the first three quarters of 2025 increased 3% to $434.6 million and 3% to $407.4 million, respectively, as compared to $421.7 million and $394.7 million in the same period of 2024.

Net income decreased to $81.2 million, or $1.58 per diluted share, through the first three quarters of 2025, as compared to $85.4 million, or $1.66 per diluted share, in the same period of 2024. During the first three quarters of 2025, we realized a negative tax impact associated with share-based awards of $0.4 million, as compared to a positive benefit of $2.2 million during the same period one year ago. Inclusive of the tax impact associated with share-based awards, Exponent’s consolidated tax rate was 28.2% through the first three quarters of 2025, as compared to 26.4% for the same period last year.

EBITDA¹ decreased to $113.4 million, or 27.8% of revenues before reimbursements, through the first three quarters of 2025, as compared to $115.8 million, or 29.3% of revenues before reimbursements, in the same period of 2024.

Through the first three quarters of 2025, Exponent paid $46.7 million in dividends, repurchased $72.7 million of common stock, and closed the period with $207.4 million in cash and cash equivalents.  

In a separate press release today, Exponent announced its quarterly cash dividend of $0.30 to be paid on December 19, 2025 and reiterated its intent to continue to pay quarterly dividends. Additionally, our Board of Directors approved an increase in our current stock repurchase program of $100 million. This is in addition to the $21.6 million available for repurchase as of October 3, 2025.

Business Overview

Exponent’s engineering and other scientific segment represented 84% of the Company’s revenues before reimbursements in the third quarter and through the first three quarters of 2025. Revenues before reimbursements in this segment increased 10% in the third quarter and 3% through the first three quarters of 2025, as compared to the prior year period. Growth during the quarter was driven by demand for Exponent's risk management and asset integrity management services in the utilities industry and dispute-related services in the energy, automotive and medical device sectors.

Exponent’s environmental and health segment represented 16% of the Company’s revenues before reimbursements in the third quarter and through the first three quarters of 2024. Revenues before reimbursements in this segment increased 9% in the third quarter and 2% through the first three quarters of 2025, as compared to the prior year period. Growth in this segment was driven by increased regulatory consulting engagements in the chemicals industry.

Business Outlook

“We delivered strong financial performance during the third quarter of 2025 and are encouraged by the influx of new engagements and high-quality talent coming into the business. We are strategically increasing headcount to support growth while generating solid utilization and strong rate realization, reflecting our differentiation in the marketplace,” commented Richard Schlenker, Executive Vice President and Chief Financial Officer. “As we close out 2025, we are maintaining our revenue guidance and raising our margin guidance for the full year. Looking ahead, our conviction in Exponent’s long-term growth trajectory remains steadfast, as reflected in the Board of Directors’ recent approval to increase our share repurchase authorization.”

Exponent is returning to a 13-week fiscal fourth quarter in 2025, which poses a headwind for comparisons since Q4 of fiscal 2024 benefited from a 14th week. For the fourth quarter of fiscal 2025 as compared to the fourth quarter of fiscal 2024, Exponent anticipates:

• Revenues before reimbursements to grow in the low to mid-single digits (high single-digit to low double-digit growth when adjusted for the extra week during Q4 of 2024); and,
• EBITDA¹ to be 26.0% to 27.0% of revenues before reimbursements.

Exponent is returning to a 52-week fiscal year in 2025, which poses a headwind for full-year comparisons since fiscal 2024 benefited from a 53rd week. For the full fiscal year 2025 as compared to fiscal year 2024, Exponent anticipates:

• Revenues before reimbursements to grow in the low single digits; and,
• EBITDA¹ to be 27.4% to 27.65% of revenues before reimbursements.

“Rapid innovation is accelerating industry transformation as companies strive to compete, while expectations for safety, health, and the environment reach new heights and the consequences of failure intensify. Exponent is uniquely positioned to capitalize on these enduring and powerful trends, driving long-term growth and value creation for our stakeholders,” concluded Dr. Corrigan.

Today's Conference Call Information

Exponent will discuss its financial results in more detail on a conference call today, Thursday, October 30, 2025, starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. The audio of the conference call is available by dialing (844) 481-2781 or (412) 317-0672. A live webcast of the call will be available on the Investor Relations section of the Company's website at www.exponent.com/investors. For those unable to listen to the live webcast, a replay of the call will also be available on the Exponent website, or by dialing (877) 344-7529 or (412) 317-0088 and entering passcode 1587971#.

Use of non-GAAP Financial Measures ¹

EBITDA is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation, and amortization. EBITDAS is a non-GAAP financial measure defined by the Company as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance and cash flow to complement operating income, net income, and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present, and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position, or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP.

Exponent has provided its outlook regarding EBITDA as a percentage of revenues before reimbursements. The Company has not reconciled this non-GAAP financial measure to the corresponding GAAP financial measure because guidance for the various reconciling items is not provided and the Company is unable to estimate with reasonable certainty the effect of these items without unreasonable effort. For example, the Company is unable to estimate with reasonable certainty the impact of equity awards on Exponent’s taxes without unreasonable effort. These items are uncertain, depend on various factors, and may have a material effect on Exponent’s results computed in accordance with GAAP. A reconciliation between the historical GAAP and non-GAAP financial measures presented in this release is provided in the financial tables at the end of this release.

About Exponent

Exponent brings together 90+ technical disciplines and 950+ consultants to help our clients navigate the increasing complexity of more than a dozen industries, connecting decades of pioneering work in failure analysis to develop solutions for a safer, healthier, more sustainable world.

Exponent’s consultants deliver the highest value by leveraging multidisciplinary expertise and resources from across Exponent’s offices in North America, Asia, and Europe. Exponent’s consultants, laboratories, databases, and computing resources work seamlessly together around the globe, enabling us to produce the breakthrough insights needed to help multinational companies, startups, law firms, insurance companies, governments, and society respond to incidents and push their products and processes forward.

Exponent may be reached at (888) 656-EXPO, info@exponent.com, or www.exponent.com.

Forward Looking Statements

This news release contains, and incorporates by reference, certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended) that are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. When used in this document and in the documents incorporated herein by reference, the words “intend,” “anticipate,” “believe,” “estimate,” “expect” and similar expressions, as they relate to the Company or its management, identify such forward-looking statements. Such statements reflect the current views of the Company or its management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include the possibility that the demand for our services may decline as a result of changes in generally applicable and industry-specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business, and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in our Annual Report on Form 10-K under the heading “Risk Factors” and elsewhere in the report. The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved. The Company undertakes no obligation to release publicly any updates or revisions to any such forward-looking statements.

Source: Exponent, Inc.

EXPONENT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
For the Quarters Ended October 3, 2025 and September 27, 2024
(unaudited)
(in thousands, except per share data)
							Quarter Ended						Nine Months Ended
							October 3,			September 27,			October 3,			September 27,
							2025			2024			2025			2024
Revenues
	Revenues before reimbursements						$	137,073		$	125,085		$	407,378		$	394,726
	Reimbursements							10,047			11,194			27,211			27,022
		Revenues						147,120			136,279			434,589			421,748
Operating expenses
	Compensation and related expenses							87,726			81,954			261,103			251,747
	Other operating expenses							12,655			11,975			36,822			33,691
	Reimbursable expenses							10,047			11,194			27,211			27,022
	General and administrative expenses							7,654			5,309			18,806			16,984
								118,082			110,432			343,942			329,444
		Operating income						29,038			25,847			90,647			92,304
Other income (expense), net
	Interest income, net							2,312			2,559			7,370			7,416
	Miscellaneous income (expense), net							7,267			7,531			15,175			16,322
								9,579			10,090			22,545			23,738
		Income before income taxes						38,617			35,937			113,192			116,042
Income taxes								10,573			9,893			31,945			30,629
		Net income					$	28,044		$	26,044		$	81,247		$	85,413
Net income per share:
	Basic						$	0.55		$	0.51		$	1.59		$	1.67
	Diluted						$	0.55		$	0.50		$	1.58		$	1.66
Shares used in per share computations:
	Basic							50,872			51,177			51,113			51,098
	Diluted							51,179			51,622			51,454			51,527

EXPONENT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
October 3, 2025 and January 3, 2025
(unaudited)
(in thousands)
						October 3,				January 3,
						2025				2025
Assets
Current assets:
	Cash and cash equivalents					$	207,380			$	258,901
	Accounts receivable, net						181,996				161,407
	Prepaid expenses and other assets						27,410				26,573
		Total current assets					416,786				446,881
Property, equipment and leasehold improvements, net							72,244				73,007
Operating lease right-of-use asset							73,312				75,248
Goodwill							8,607				8,607
Other assets							190,500				173,527
						$	761,449			$	777,270
Liabilities and Stockholders' Equity
Current liabilities:
	Accounts payable and accrued liabilities					$	26,453			$	22,136
	Accrued payroll and employee benefits						108,922				119,285
	Deferred revenues						12,902				16,369
	Operating lease liability						6,490				5,393
		Total current liabilities					154,767				163,183
Other liabilities							127,713				116,935
Operating lease liability							76,108				76,084
		Total liabilities					358,588				356,202
Stockholders' equity:
	Common stock						66				66
	Additional paid-in capital						367,010				345,689
	Accumulated other comprehensive loss						(2,402	)			(3,791	)
	Retained earnings						658,788				624,151
	Treasury stock, at cost						(620,601	)			(545,047	)
			Total stockholders' equity				402,861				421,068
						$	761,449			$	777,270

EXPONENT, INC.
EBITDA and EBITDAS (1)
For the Quarters Ended October 3, 2025 and September 27, 2024
(unaudited)
(in thousands)
							Quarter Ended								Nine Months Ended
							October 3,				September 27,				October 3,				September 27,
							2025				2024				2025				2024
Net Income							$	28,044			$	26,044			$	81,247			$	85,413
Add back (subtract):
	Income taxes							10,573				9,893				31,945				30,629
	Interest income, net							(2,312	)			(2,559	)			(7,370	)			(7,416	)
	Depreciation and amortization							2,532				2,389				7,544				7,199
		EBITDA (1)						38,837				35,767				113,366				115,825
	Stock-based compensation							5,341				5,465				18,767				18,382
		EBITDAS (1)					$	44,178			$	41,232			$	132,133			$	134,207
(1) EBITDA is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation and amortization. EBITDAS is a non-GAAP financial measure defined by the Company as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance and cash flow to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP.

FAQ

What were Exponent (EXPO) third-quarter fiscal 2025 revenues and EPS on Oct 30, 2025?

Q3 fiscal 2025 total revenues were $147.1M and net income was $28.0M, or $0.55 per diluted share.

How did Exponent (EXPO) perform year-to-date through Q3 2025 and what changed vs 2024?

Through three quarters of 2025, revenues were $434.6M (up 3%) and net income was $81.2M (down vs $85.4M in 2024).

What buyback and dividend actions did Exponent (EXPO) announce on Oct 30, 2025?

The Board approved a $100M increase to the repurchase program; Exponent declared a quarterly cash dividend of $0.30 payable Dec 19, 2025.

What EBITDA guidance did Exponent (EXPO) give for Q4 and full-year fiscal 2025?

Exponent expects Q4 EBITDA of 26.0%–27.0% of revenues before reimbursements and full-year EBITDA of 27.4%–27.65%.

Will Exponent’s fiscal calendar affect comparability for Q4 2025 results?

Yes. Exponent returns to a 13-week Q4 in 2025 (vs a 14-week Q4 in 2024), and the full year returns to 52 weeks (vs 53 weeks in 2024), creating timing headwinds for comparisons.